



## **Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day**

March 29, 2021 at 7:00 AM EDT

DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and *in vivo* gene correction therapies with its ARCUS® genome editing platform, today announced it will participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day on April 1, 2021.

Details for the presentation are below:

### **Guggenheim Healthcare Talks | 2021 Genomic Medicines & Rare Disease Day**

**Panel:** On the Cusp of Genomic Medicine and Cell Therapy for Dyslipidemia and T1DM

**Presenter:** Derek Jantz, Ph.D., Chief Scientific Officer

**Date:** Thursday, April 1, 2021

**Time:** 8:00-8:50 AM ET

A live webcast of the presentation will be accessible on the Company's website, [www.precisionbiosciences.com](http://www.precisionbiosciences.com), in the Investors & Media section under Events and Presentations. An archived replay of the webcasts will be available for approximately 30 days following the presentation.

### **About Precision BioSciences, Inc.**

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple "off-the-shelf" CAR T immunotherapy clinical candidates and several *in vivo* gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist. For more information about Precision BioSciences, please visit [www.precisionbiosciences.com](http://www.precisionbiosciences.com).

### **Investor Contact:**

Alex Kelly

Interim Chief Financial Officer

[Alex.Kelly@precisionbiosciences.com](mailto:Alex.Kelly@precisionbiosciences.com)

### **Media Contact:**

Maurissa Messier

Senior Director, Corporate Communications

[Maurissa.Messier@precisionbiosciences.com](mailto:Maurissa.Messier@precisionbiosciences.com)